.png){kind=icon}
.png){kind=icon}
Return
Enzalutamide with or without leuprolide in patients with high-risk biochemically recurrent prostate cancer: EMBARK post hoc analysis by age
.png){kind=icon}
PRE
AI
DOI：10.1016/j.ejca.2025.116110.png)
.png){kind=icon}
Original request for help.png){kind=icon}
Share.png){kind=icon}
Save
Abstract
En 中文
• First analysis of impact of age on enzalutamide in high-risk biochemical recurrence • Metastasis-free survival favored enzalutamide ± leuprolide in aged ≥70 or <70 years • Patients aged ≥70 years had increased incidence of adverse events
Journal
IF:
7.1
Papers:
2.6W
Citations:
3.8W
Organization
View more organizations